Extended Data Fig. 1: Comparison of the CAR T cell ex vivo PEGylation strategy with the in situ PEGylation strategy.
From: In situ PEGylation of CAR T cells alleviates cytokine release syndrome and neurotoxicity
a, Raji tumour-bearing mouse model was constructed, and mice were treated with either ex vivo PEGylated CAR T cells or regular CAR T-azide cells at day 0. On day 1, the mice receiving regular CAR T-azide cells developed high fever (ΔT > 2 °C), after which DBCO-PEG600k (in situ PEGylation) was injected. Mouse body temperature (b), tumour burden (c), blood IL-6 levels (d) and CAR T cell levels (e) were monitored. f, quantification of tumour burden in different groups at day 35. g, Kaplan–Meyer survival plots. Data in (b), (d), (e), and (f) are shown as mean ± s.d. (n = 5). Statistical differences in (b), (d), and (e) were calculated using two-way ANOVA with Tukey’s post hoc test. Statistical differences in (f) were calculated using one-way ANOVA with Tukey’s post hoc test. P values indicated in the figure are from the comparisons on day 7. Statistical differences in (g) were conducted using a Mantel–Cox two-sided log-rank test (n = 5). P values are indicated.
